Preparation and characterization of controlled release poly-e{open}-caprolactone microparticles of isoniazid for drug delivery through pulmonary route

Powder Technology

Volumn 264, Issue , 2014, Pages 158-165

  Parikh, Rajesh ^a   Dalwadi, Sonali ^a  

^a CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Inhaled; Isoniazid; Microparticles; Polymer; Pulmonary; Tuberculosis

Indexed keywords

BACILLI; BIOLOGICAL ORGANS; DEPOSITION; DRUG DELIVERY; EMULSIONS; KINETIC PARAMETERS; KINETIC THEORY; POLYMERS; SPRAY DRYING;

INHALED; ISONIAZID; MICRO-PARTICLES; PULMONARY; TUBERCULOSIS;

HYDRAZINE;

ISONIAZID; NANOPARTICLE; POLYCAPROLACTONE; POLYMER;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG UPTAKE; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; PARTICLE SIZE; PH; SIMULATION; SPRAY DRYING; SURFACE PROPERTY; SYNTHESIS;

EID: 84902107533     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2014.04.077     Document Type: Article

References (33)

1. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb.) 2010, 1-11.
2. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25(12):563-570.
3. Boer AHd, Molema G, Frijlink HW. 2001. Pulmonary drug delivery: delivery to and through the lung. In Molema G, Meijer DKF, editors. Drug targeting organ-specific strategies, ed., NY: Wiley-VCH Verlag GmbH. p 53-88.
4. O'Hara P., Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 2000, 17(8):955-961.
5. Sung J.C., Padilla D.J., Garcia-Contreras L., VerBerkmoes J.L., Durbin D., Peloquin C.A., Elbert K.J., Hickey A.J., Edwards D.A. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 2009, 26(8):1847-1855.
6. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 2001, 48(3):431-434.
7. Sharma R., Saxena D., Dwivedi A.K., Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18(10):1405-1410.
8. Vyas S., Kannan M., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004, 269(1):37-49.
9. Fdr Tewes, Brillault J., Couet W., Olivier J.-C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control. Release 2008, 129(2):93-99.
10. du Toit L.C., Pillay V., Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. 2006, 7:118.
11. Barrow E.L.W., Winchester G.A., Staas J.K., Quenelle D.C., Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 1998, 42(10):2682-2689.
12. Zahoor A., Sharma S., Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 2005, 26(4):298-303.
13. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb.) 2005, 85(4):227-234.
14. Deol P., Khuller G.K., Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 1997, 41(6):1211-1214.
15. Sung J., Pulliam B., Edwards D. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 21(12):563-570.
16. Blomberg Br, Spinaci S., Fourie B., Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 2001, 79:61-68.
17. Verma R.K., Kaur J., Kumar K., Yadav A.B., Misra A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 2008, 52(9):3195-3201.
18. Tiwari S., Chaturvedi A.P., Tripathi Y.B., Mishra B. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSciTech 2011, 12(3):900-908.
19. Rojanarat W., Changsan N., Tawithong E., Pinsuwan S., Chan H.-K., Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci. 2011, 12(7):4414-4434.
20. Durán N., De Oliveira A.F., De Azevedo M.M. In vitro studies on the release of isoniazid incorporated in poly(îμ-caprolactone). J. Chemother. 2006, 18(5):473-479.
21. Chow A.L., Tong H.Y., Chattopadhyay P., Shekunov B. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24(3):411-437.
22. RÃ(c) M-Is Formulating drug delivery systems by spray drying. Dry. Technol. 2006, 24(4):433-446.
23. El-Gendy N., Bailey M.M., Berkland C. Particle engineering technologies for pulmonary drug delivery. Controlled pulmonary drug delivery 2011, 283-312. Springer.
24. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32(2):140-150.
25. Marques M.R., Loebenberg R., Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolut. Technol. 2011, 18(3):15-28.
26. Costa P., Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13(2):123-133.
27. Dhakar R.C. From formulation variables to drug entrapment efficiency of microspheres: a technical review. J. Drug Deliv. Ther. 2012, 2(6).
28. Sharma G., Valenta D.T., Altman Y., Harvey S., Xie H., Mitragotri S., Smith J.W. Polymer particle shape independently influences binding and internalization by macrophages. J. Control. Release 2010, 147(3):408-412.
29. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 2007, 121(1â€"2):3-9.
30. Verma R.K., Singh A.K., Mohan M., Agrawal A.K., Misra A. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther. Deliv. 2011, 2(6):753-768.
31. Sansone F., Aquino R.P., Gaudio P.D., Colombo P., Russo P. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying. Eur. J. Pharm. Biopharm. 2009, 72(1):206-213.
32. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 2008, 25(5):999-1022.
33. Coowanitwong I., Arya V., Kulvanich P., Hochhaus Gn Slow release formulations of inhaled rifampin. AAPS J. 2008, 10(2):342-348.